Netherlands· NL-85cef4fc7108
Idefirix 11 mg, poeder voor concentraat voor oplossing voor infusie
A imlifidase product containing imlifidase, registered in Netherlands by Hansa Biopharma AB. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Imlifidase is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AA41 (imlifidase), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Imlifidase · ATC L04AA41
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of imlifidase costs, country by country.
Normalised to the WHO defined daily dose (17.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Imlifidase · price per daily dose (17.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$271803.14
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- IMLIFIDASE
- Manufacturer
- Hansa Biopharma AB
- Country
- Netherlands (NL)
- ATC code
- L04AA41
- ATC class
- Imlifidase
- Defined daily dose
- 17.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/20/1471
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imlifidase in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceIDEFIRIX 11 mg, poudre pour solution à diluer pour perfusionHANSA BIOPHARMA (SUEDE)
- CzechiaIDEFIRIXHansa Biopharma AB, Lund
- SwitzerlandIdefirix
- FinlandIdefirixHansa Biopharma AB
- United KingdomIdefirix 11mg powder for concentrate for solution for infusion vialsHansa Biopharma AB
- IrelandIdefirix 11 mg powder for concentrate for solution for infusionHansa Biopharma AB
- IcelandIdefirixHansa Biopharma AB
- NorwayIdefirixHansa Biopharma AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Idefirix
- Liechtenstein · Idefirix
- Norway · Idefirix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a91b99b7-790e-4f94-bc5d-a2dc5248df21 GET /v1/drugs/a91b99b7-790e-4f94-bc5d-a2dc5248df21?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Imlifidase",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp124521",
"excipients": [
"DINATRIUMEDETAAT 2-WATER",
"MANNITOL (D-) (E 421)",
"POLYSORBAAT 80 (E 433)",
"STIKSTOF (HEAD SPACE) (E 941)",
"TROMETAMOL",
"ZOUTZUUR (E 507)"
],
"substances": [
"IMLIFIDASE"
],
"leaflet_url": null,
"authorised_at": "2020/08/25",
"procedure_number": "EMEA/H/C/004849",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/20/1471",
"additional_monitoring": "Y"
}See everything about imlifidase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.